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KEY POINTS
 Although the evidence has been conflicting, it seems that the linkage between alcoholic
liver disease (ALD)–associated compensated cirrhosis and hepatocellular carcinoma
(HCC) is best characterized as medium–high risk.
 Alcohol interacts with other causes of liver disease, including hepatitis B and C, and con-
ditions, such as diabetes and obesity, to increase the risk for developing HCC, either syn-
ergistically or additively.
 HCC risk in patients with ALD-associated cirrhosis increases with age and with quantity
and duration of alcohol consumption and is pronounced in women.INTRODUCTION
In the United States, alcoholic liver disease (ALD) is the second leading cause of liver
transplantation and cirrhosis behind chronic infection with hepatitis C virus (HCV).1–3
Globally, alcohol accounts for 50% of all deaths due to cirrhosis.4 The clinical spec-
trum of ALD includes steatosis, sclerosing hyaline necrosis, acute on chronic liver fail-
ure, alcoholic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Although the
prevalence of ALD-associated cirrhosis (defined here as cirrhosis that develops exclu-
sively as the result of alcohol intake, with no other contributing factors) is high globally,The authors have nothing to disclose.
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Joshi et al564the incidence of HCC associated with alcoholic cirrhosis is lower than the incidence
associated with cirrhosis of other etiologies, including chronic HCV, chronic hepatitis
B virus (HBV), and hereditary hemochromatosis.5 To better understand the relation-
ship between ALD and the development of HCC, several studies have investigated
alcohol as the primary cause and as a cofactor for carcinogenesis along with other eti-
ologies of liver disease, such as viral hepatitis, hemochromatosis, and fatty liver dis-
ease. Additionally, studies have shown that host factors such as gender, genetics,
and ethnicity may influence disease progression. This review critically assesses the
literature to evaluate the risk posed by alcohol as a primary cause of and as a cofactor
for the development of HCC.
AS A PRIMARY CAUSE: THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH
ALCOHOLIC LIVER DISEASE–ASSOCIATED CIRRHOSIS
There have been conflicting findings on the level of HCC risk in patients with compen-
sated ALD-associated cirrhosis. Seven studies evaluating HCC risk in patients with
cirrhosis associated exclusively with alcohol consumption (with no evidence of ongoing
viral hepatitis infection) have suggested that the 10-year cumulative incidence may
range from 6.8-28.7%.6–12 In some of these studies, patients with ALD-associated
cirrhosis were evaluated alongside patients with chronic hepatitis B (CHB)- and chronic
hepatitis C (CHC)-associated cirrhosis.6,9,11,12 (Tables 1 and 2).Table 1
Summary of key studies investigating hepatocellular carcinoma risk for patients with
compensated alcoholic cirrhosis (without concomitant viral hepatitis)
Study Country
Total
Patients (n) Follow-up (y) Age (y)
Male/
Female
Hepatocellular
Carcinoma
Cumulative
Incidence
Toshikuni et al,6
2009
Japan 227 3.5b 59b 67/8 Annual: 0.6%
3-y: 1.3%
5-y: 6.8%
7-y: 6.8%
10-y: 6.8%
Jepsen et al,7 2012 Demark 8482 4.1b 54.4b 5655/2827 5-y: 1.0%
Ioannou et al,11
2007
USA 2126 3.6a NA 2062/64 0.6/100
Patient-years
Uetake et al,8 2003 Japan 91 5.9b 50.1b 91/0 3-y: 2.4%
5-y: 6.4%
7-y: 18.9%
10-y: 28.7%
N0Kontchou et al,9
2006
France 771 4.1a 59.7a 336/142 5-y: 16%
Mancebo et al,10
2013
Spain 450 3.5b 53.9a 369/81 Annual: 2.6%
5-y: 13.2%
10-y: 23.2%
Lin et al,12 2013 Taiwan 966 5.2a 49.3b 165/37 Annual: 1.9%
3-y: 4.8%
5-y: 8.9%
10-y: 21.4%
a Mean.
b Median.
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Two of the studies outlined in Table 1 evaluated the risk of HCC in patients with ALD-
associated cirrhosis and suggested that the risk is low. With subgroup analysis,
however, certain categories of patients are shown to have higher HCC risk. A large
retrospective population-based study of 8482 Danish patients with ALD-associated
cirrhosis found a 5-year cumulative risk for developing HCC of 1%.7 A stratified anal-
ysis, however, found several demographic groupswho exhibited a higher risk for devel-
oping HCC. Men (n 5 5,655) had a 5-year risk of 1.5% (95% CI, 12–1.8) which was
several-fold greater than the 5-year risk for women (n 5 2,827) of 0.2% (95% CI,
0.1–0.4). Additionally, the risk for developing HCC increased with age. Approximately
33% of the cohort was less than 50 years old and had a 5-year HCC risk of 0.3% (95%
CI, 0.1–0.5). In contrast, patients who were greater than or equal to 70 years old had a
nearly 6.5-fold greater risk of 1.9% (95% CI, 1.0–3.3). In addition, an analysis of a sub-
set of patients (n 5 320) whose diagnosis of cirrhosis was corroborated by additional
chart reviews and who were followed up by hepatologists found the 5-year HCC risk to
be 1.9%. This was nearly double that of the primary group, suggesting a potential
misclassification bias of the primary cohort and an underestimation of HCC risk.
Another retrospective study of 2,126 cirrhotic patients seen at United States Veter-
ans Affairs centers evaluated the incidence and predictors of HCC.11 Among the 734
patients (35% of the population) with ALD-associated cirrhosis, the aggregate HCC
incidence was only 0.6 per 100 patient-years. In contrast, patients with chronic HBV-
associated and chronic HCV-associated cirrhosis had HCC incidence rates of 2.4
and 3.6 per 100 patient years, respectively. Because of its scale and design, this study
was able to identify seven risk factors for the development of HCC in cirrhotics and
adjust for key confounding variables. Ultimately, HCC incidence rates changed more
than 20-fold depending on the presence of other risk factors evaluated in the study:
CHC, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc),
obesity, overweight, diabetes, and gradations of low platelets (Table 2). Significantly,
alcohol only, as a cause of cirrhosis, was not implicated as a risk factor for HCC.Evidence Suggesting Patients with Alcoholic Cirrhosis are at Medium–High Risk for
Hepatocellular Carcinoma
Conversely, the other 5 studies outlined in Table 1 suggest that patients with ALD-
associated cirrhosis are at a medium–high risk (10-year cumulative risk 21.4%–
28.7%) for the development of HCC.6,8–10,12 A prospective cohort study following
91 Japanese males with compensated alcoholic cirrhosis who were HBsAg-negative
and anti-HCV-negative reported a 6.4% (5-year) and 28.7% (10-year) cumulative inci-
dence of HCC.8 In comparing alcoholic cirrhotic patients with (n 5 13) and without
(n 5 78) HCC, two critical differences were observed. Those with HCC had a far
greater lifetime cumulative alcohol consumption (P 5 .0047) and were more likely to
have been exposed to HBV (P 5 .0598) as evidenced by the presence of anti-HBc.
The 3, 5, 7, and 10-year cumulative incidence rates of HCC were 8.4%, 19.9%,
33.2%, and 41.6% in the subset of alcoholic cirrhotics whose cumulative alcohol con-
sumption exceeded 1200 kg compared to 0%, 2.0%, 10.8%, and 20.7%, respectively,
in patients with a cumulative alcohol consumption less than 1200 kg.
Similarly, a prospective cohort study following 478 patients with well-compensated
ALD-associated cirrhosis without viral hepatitis found a medium risk for developing
HCC.9 N’Kontchou and colleagues reported a 5-year HCC cumulative incidence rate
of 16% and identified four independent predictors of HCC in alcoholic cirrhotics: age
Table 2
Comparison of the effects of risk factors on the development of hepatocellular carcinoma in patients with cirrhosis
Study Study Design Risk Factors Evaluated Reference Point
Hazard Ratio (HR)/
Odds Ratio (OR)/
Relative Risk
(RR)/Regression
Coefficient (RC) 95% CI P value
Chung et al,38
2007
Retrospective HCC risk
HBV and ethanol cirrhosis Ethanol-only cirrhosis OR 17.609
NR
P 5 .001
HBV cirrhosis OR 8.449 P 5 .001
Age OR 1.056 P 5 .001
Donato et al,20
2002
Case-controla HCC risk
HBV (), HCV (), consumes
>60 g/d
HBV () and HCV () and
consumes 0–60 g/d
OR 7.0 4.5–11.1
NR
HBV (1), consumes 0–60 g/d OR 22.8 12.1–42.8
HBV (1), consumes >60 g/d OR 48.6 24.1–98.0
HCV (1), consumes 0–60 g/d OR 55.0 29.9–101
HCV (1), consumes >60 g/d OR 109 50.9–233
Wang et al,39
2003
Population-
based
cohort
HCC risk
Age Age: 30–39 RR
NR
40–49 4.39 1.90–10.14
50–59 9.22 4.20–20.24
601 9.63 4.16–22.28
Residence: Penghu Islets Residence: Taiwan Island RR 2.06 1.41–3.00
HBsAg serostatus: (1) () HBsAg RR 13.14 8.60–20.08
Anti-HCV serostatus: (1) () Anti-HCV RR 2.45 1.42–4.22
Years of schooling  <6 y of schooling RR
6 0.75 0.45–1.25
 >6 0.72 0.41–1.28
Ethnicity Ethnicity: Fukienese RR
Hakka 1.66 0.94–2.94
China Mainlander/aborigine 0.80 0.39–1.67
Cigarette smoking: yes No cigarette smoking RR 1.55 1.06–2.26
Duration of cigarette smoking (y) Nonsmokers RR
1–25 0.98 0.54–1.77
 >25 1.91 1.25–2.91
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Alcohol drinking: yes No alcohol drinking RR 1.46 0.97–2.21
Duration of alcohol drinking (y) Nondrinkers RR
1–20 1.34 0.64–2.79
 >20 1.56 0.95–2.55
Betel quid chewing: yes No betel quid chewing RR 1.59 0.89–2.85
Quantity betel quid chewed/d Nonchewer RR
1–10 1.44 0.66–3.14
 >10 1.92 0.87–4.22
No. substance use habits 0 Substance abuse habits RR
1 1.36 0.88–2.01
2 1.60 0.95–2.70
3 3.15 1.45–6.89
Familial history HCC
(1st-degree relatives): yes
No familial HCC history
(1st-degree relatives)
RR 1.46 0.68–3.15
Liver function at recruitment
(AST >30 or ALT >35):
dysfunction
Normal liver function at
recruitment
RR 3.15 2.13–4.67
Tagger et al,46
1999
Case-controlb HCC risk
NR
HCV RNA (1) and ethanol HCV RNA () and ethanol
0–40 g/d
OR
0–40 g/d 26.1 12.6–54.0
41–80 g/d 62.6 23.3–168
 >80 g/d 126 42.8–373
HCV RNA (1) and HBsAg () HCV RNA () and HBsAg () OR 35.6 14.5–87.1
HCV RNA () and HBsAg (1) — OR 21.1 11.1–40.0
HCV RNA (1) and HBsAg (1) — OR 132 15.3–890
HCV RNA () and anti-HBs (1),
anti-HBc (1) or anti-HBs (1)
alone
— OR 1.3 0.8–2.1
HCV RNA (1) and anti-HBs (1),
anti-HBc (1) or anti-HBs (1)
alone
— OR 36.5 16.0–83.1
HCV RNA () and anti-HBc (1) — OR 1.7 1.0–2.9
HCV RNA (1) and anti-HBc (1) — OR 29.8 10.9–56.8
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Table 2
(continued )
Study Study Design Risk Factors Evaluated Reference Point
Hazard Ratio (HR)/
Odds Ratio (OR)/
Relative Risk
(RR)/Regression
Coefficient (RC) 95% CI P value
Tsutsumi et al,47
1996
Retrospective HCC risk for the following causes of cirrhosis
Ethanol No evidence of HBV, HCV, or
alcohol in developing cirrhosis
or HCC
OR 1.22
NR NR
HBV OR 4.49
HCV OR 2.39
HBV 1 ethanol OR 4.96
HCV 1 ethanol OR 5.28
HBV 1 HCV OR 3.01
Miyakawa
et al,67 1993
Retrospective HCC risk
Ethanol cirrhosis
NR
OR 0.615
NR
NS
HCV cirrhosis OR 1.90 P<.05
HCV and ethanol Cirrhosis OR 3.65 P<.01
Child-Pugh A OR 0.653 P<.05
Male gender OR 2.06 P<.01
Uetake et al,8
2003
Prospective HCC risk in ethanol cirrhotics (without HBV or HCV)
Cumulative alcohol intake NR RC 0.0017; Z 2.83 NR P 5 .0047
(1) Anti-HBc RC 1.1533; Z 1.88 P 5 .0598
Aizawa et al,44
2000
Retrospective HCC risk in chronic HCV patients
Age 50 Age <50 RR 4.54 2.06–9.98 P 5 .0002
Male gender Female gender RR 2.80 0.92–8.52 P 5 .07
Ethanol consumption 65 g/d >5 y
(habitual heavy drinking)
No habitual heavy drinking RR 3.04 1.31–7.09 P 5 .01
Minimum ALT 40 ALT, 40 RR 1.80 0.84–3.87 P 5 .13
IFN therapy No IFN therapy RR 0.78 0.30–1.98 P 5 .596
Staging (severe fibrosis) Mild staging RR 3.48 1.51–8.06 P 5 .004
Irregular regeneration (severe) Mild regeneration RR 1.19 0.45–3.20 P 5 .724
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Ioannou et al,11
2007
Retrospective HCC risk in cirrhotics
HCV NR HR 3.0 1.7–5.3
NR
HBsAg HR 3.3 1.4–7.7
Anti-HBc HR 1.7 1.1–2.8
BMI BMI <25 HR
25–30 2.8 1.5–5.4
30 2.5 1.3–4.9
Diabetes NR HR 1.5 0.9–2.5
Platelet count Platelet count >266 HR
180–266 2.1 0.8–5.6
111–179 3.3 1.3–8.0
 <111 4.7 2.0–11.4
Kwon et al,41
2012
Case-controlc HCC risk
(1) Anti-HBc Patients with cirrhosis
and anti-HBc ()
OR 3.1 1.354–7.098 P 5 .007
(1) Anti-HBc and (1) anti-HBs OR 2.61 1.090–6.287 P 5 .031
(1) Anti-HBc and () anti-HBs OR 4.16 1.571–11.01 P 5 .004
(1) Anti-HBc and () HBV DNA OR 2.7 1.12–6.49 P 5 .027
(1) Anti-HBc and (1) HBV DNA OR 3.13 1.11–8.81 P 5 .039
Mancebo et al,10
2013
Prospective HCC risk in ethanol cirrhotics
Age 55 NR HR 2.39 1.27–4.51 P 5 .007
Platelets <125 HR 3.29 1.39–7.85 P 5 .007
N’Kontchou
et al,9 2006
Prospective HCC risk in cirrhotics (HCV, ethanol, HCV 1 ethanol)
Age Age: <50 HR
50–60 1.6 0.9–2.9 P 5 NS
60–70 2.4 1.3–4.3 P 5 .005
>70 3.0 1.7–5.5 P<.0001
Male gender Gender: female HR 2.0 1.4–2.7 P<.0001
Cirrhosis cause Cirrhosis cause: ethanol HR
HCV 1.6 1.2–2.2 P 5 .002
HCV and ethanol 2.6 1.7–4.0 P<.0001
BMI BMI: <25 HR
25–30 2.0 14–2.7 P<.0001
30 2.8 2.0–4.0 P<.0001
Diabetes Diabetes: no HR 1.6 1.2–2.1 P 5 .001
(continued on next page)
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Table 2
(continued )
Study Study Design Risk Factors Evaluated Reference Point
Hazard Ratio (HR)/
Odds Ratio (OR)/
Relative Risk
(RR)/Regression
Coefficient (RC) 95% CI P value
Marrero et al,66
2005
Case-controlc HCC risk Cirrhotic patients
Alcohol (gram-years) Alcohol: none OR
NR
<1500 0.5 0.1–0.7
1500 5.7 2.4–13.7
Tobacco (pack-years) Tobacco: none OR
<20 0.7 0.4–1.2
20 4.9 2.2–10.6
BMI Obesity: lean OR
25.1–30 0.3 0.09–0.5
30 4.3 2.1–8.4
Loomba et al,65
2010
Prospective HCC risk in REVEAL-HBV cohort
BMI and ethanol usage BMI <30 and no ethanol use BMI and ethanol
usage
BMI and
ethanol
usage
BMI and
ethanol
usage
BMI 30, no use HR 0.64 0.16–2.63 P 5 .5385
BMI <30, yes use HR 1.64 1.12–2.40 P 5 .0106
BMI 30, yes use HR 3.40 1.24–9.34 P 5 .0176
Abbreviations: NR, not reported; NS, not significant.
a Controls did not have liver disease, although consumed alcohol.
b Controls did not have HCC, but some had HCV or HBV; Number with cirrhosis not reported.
c Controls were cirrhosis (1) and HCC ().
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Alcoholic Liver Disease 571>70, male gender, having a BMI 30, and diabetes (see Table 2). Similar to other
studies, this study did not report any data on volume of alcohol consumption. Likewise,
a prospective study following 450 patients with compensated ALD-associated
cirrhosis reported an annual HCC incidence of 2.6%, along with 5 and 10-year cumu-
lative rates of 13.2% and 23.2%, respectively.10 Multivariate analysis identified two
independent risk factors for developing HCC, age 55 and having a platelet count
less than 125 (see Table 2). Based on the presence or absence of these critical factors,
the HCC risk varied dramatically. Patients who lacked both risk factors (n5 93) had an
annual HCC incidence of 0.3%compared to 2.6% in thosewith one risk factor (n5 228)
and 4.8% in those with both risk factors (n5 129). To ensure the validity of these find-
ings, the same analysis was performed in a subset of 140 patients with histologically
confirmed alcoholic cirrhosis. Similar annual incidences of HCC were observed: 0%,
2.7%, and 3.4% for patients with 0, 1, and 2 risk factors, respectively.
A retrospective cohort study of Japanese patients with compensated cirrhosis
observed annual and 5-year cumulative incidence rates of 0.6% and 6.8%, respectively.
Additionally, this study reported 10-year HCC cumulative incidence rates that were
approximately 7.5 fold higher in patients with CHC-associated cirrhosis (n 5 152)
compared to those with ALD-associated cirrhosis, 50.3% and 6.8%, respectively
(P 5 .0003).6 Finally, a Taiwanese retrospective cohort study following 966 cirrhotic pa-
tients further reinforced the notion that ALD-associated cirrhosis poses a more than
modest risk for the development of HCC.12 The study cohort consisted of patients with
three etiologies of cirrhosis: CHB alone (n5 632), combined CHB and alcohol (n5 132)
andalcohol alone (n5 202).Within the alcoholic cirrhosis subset, among the 110 patients
whowereChild-PughGrade A the annual, 5-year, and 10-year HCC incidence rateswere
1.9%, 8.9%, and 21.4%. The aforementioned incidence rates were all higher when pa-
tients with decompensated alcoholic-cirrhosis, Child-Pugh Grades A-C, were included.
In summary, the interpretationof findings fromthesekeystudies is complicatedby the
heterogeneity in study design, especially with respect to patient populations analyzed
(beyond cause), mixed causes of liver cirrhosis, evaluation of liver fibrosis, definition
of liver cirrhosis, utilization of HCC surveillance, adjustments for key confounding vari-
ables, and the extent towhich alcohol consumptionwas assessed (seeTable 1). Never-
theless, there is solid support for a medium-high risk linkage between ALD and HCC,
with risk increasing with age, cumulative lifetime alcohol consumption, and the pres-
ence of additional causes of liver disease. A more refined risk determination for the
development of HCC can be readily achieved by incorporating the risk factors reported
inmany studies (seeTable 2). The use of these findings tomanageHCC risk for patients
with ALD-associated cirrhosis is particularly important because of the paucity of evi-
dence on the use of biomarkers, such as a-fetoprotein (AFP) , a-fetoprotein–L3 (AFP-
L3), and des-gamma carboxyprothrombin (DCP) for HCC surveillance in this patient
population.13 Ultimately, to develop a comprehensive understanding of alcohol and
its relationship to HCC, it is necessary to also examine the interaction of alcohol and
HCC with different host factors, etiologies of liver disease, and comorbidities.ALCOHOL CONSUMPTION PATTERNS AND HOST FACTORS
Although quantity and duration of alcohol consumption have been associated with
ALD progression14 and an increased risk for developing HCC,15 not all patients who
chronically overconsume alcohol develop alcoholic cirrhosis and/or HCC. Instead,
progression to ALD is influenced by the interaction between consumption and a
constellation of host factors, leading to the development of cirrhosis and HCC in
only a subset of patients.
Joshi et al572Alcohol Consumption and Alcoholic Liver Disease Risk: Dose Dependent or Threshold
Effect?
Many studies have investigated whether a discrete threshold of consumption or dose
dependence characterizes the relationship between alcohol consumption and the
development of cirrhosis and/or HCC. Some studies have suggested that a threshold
delineating safe alcohol consumption from risky behavior may exist.16,17 A retrospec-
tive study of 210 deceased males found that consumption less than 40 g per day over
a 25-year period did not increase the incidence of ALD. Other studies have suggested
that this threshold may be lower. A population-based, cross-sectional study surveying
2 northern Italian towns found that the risk threshold for developing cirrhosis was
greater than 30 g per day, equivalent to a lifetime intake of 100 kg.17 In this study,
the lower risk threshold was independent of gender and the risk of cirrhosis below
this threshold was minimal. A meta-analysis found an even lower threshold for
cirrhosis development of 25 g per day.18
Conversely, other studies have found evidence of a dose-response relationship
between alcohol consumption and the development of cirrhosis.19–21 In a large-
scale prospective population study, a dose-dependent curve emerged for the devel-
opment of alcohol-induced cirrhosis in men and women.19 Women had a higher risk
for developing cirrhosis at a lower intake than men, with increased risk seen at a
weekly consumption of 84 g to 156 g compared with 168 g to 324 g for men. A similar
trend was seen for the development of HCC in a hospital-based case-control study
(n 5 464 HCC patients) where women had a nearly 5-fold higher risk for developing
HCC with heavy alcohol consumption of greater than 80 g per day (adjusted
OR 7.5).20
There does not seem to be a level of alcohol intake that absolutely equates with
cirrhosis in all people. In the Dionysos Study, a large cohort study of the prevalence
of chronic liver disease in the general population of two northern Italian communities
that included 6,534 people free of virus-related chronic liver disease, at the lowest
level of intake found to be associated with either cirrhosis or non-cirrhotic liver dam-
age (NCLD), more than 30 g per day, 2.2% became cirrhotic and 3.3% showed persis-
tent signs of NCLD; at the highest level of consumption, more than120 g per day, only
13.5% either developed cirrhosis or showed signs of liver damage.17
In summary, there is likely neither a strict, linear dose-dependent relationship nor is
there a universally accepted threshold that characterizes the relationship between
alcohol consumption and the risk for developing cirrhosis and/or HCC. Evidence sug-
gests, however, that the risk increases appreciably, albeit at different rates for each
gender, when consumption exceeds certain levels. The magnitude of this increased
risk remains difficult to ascertain for two structural reasons. For one, some influential
case-control studies utilized healthy controls20 which often contributes to an overes-
timation of risk.22 Additionally, multiple meta-analyses have reported, and to some
extent quantified, the effects of heterogeneity in study design, study endpoint, and
geographic area of study on risk estimates.15,18,21Drinking Patterns: With or Without a Meal
Multiple studies have shown that the risk for developing alcoholic cirrhosis and ALD is
increased when alcohol is consumed without any accompanying food.17,23 Bellentani
and colleagues17 found an OR of 3.4 (95% CI, 1.7–6.6) favoring the development of
cirrhosis when drinking outside of a meal. Similarly, a population-based study in China
found that those who drank without food were 2.7 times more likely to develop ALD. It
is likely that this increased risk can be explained by differences in absorption and
Alcoholic Liver Disease 573volume of distribution. To date, no study has directly evaluated the risk of developing
HCC from consuming alcohol with or without food.
The Effect of Abstinence on the Risk of Cirrhosis and Hepatocellular Carcinoma
Paradoxically, multiple studies have shown that patients with alcoholic cirrhosis who
abstain from further alcohol consumption are at a higher risk for developing HCC
than ongoing drinkers at the same intake levels.20,24 This counterintuitive finding
might be explained by considering the often large degree of liver damage that has
developed by the time a patient completely and permanently abstains from alcohol;
the profound damage to the liver parenchyma is often a precursor to irreversible dis-
ease progression and/or HCC.
Evidence also exists, however, suggesting that with sufficient time after cessation of
alcohol consumption, the risk of developing HCC in abstaining patients with ALD-
associated cirrhosis can eventually approach the risk faced by those who have never
consumed alcohol. In a comprehensive meta-analysis, Heckley and colleagues25
showed that the risk of developing HCC may drop by as much as 6% to 7% per
year after abstinence is begun. Even more encouraging, after 23 years of continued
abstinence, the risk of developing HCC may normalize and become equivalent to
the level faced by someone who has never consumed alcohol. However, the authors
from this important study warn that this estimate has a high degree of statistical uncer-
tainty, as evidenced by the wide 95% confidence interval for the time scale needed to
achieve a normalized risk for HCC.
Gender and Hormones
Women are at a higher risk for developing cirrhosis and HCC at lower levels of alcohol
consumption than their male counterparts. Some evidence suggests this higher risk
for developing cirrhosis remains for women even during abstinence.26 In a seminal
study, it was found that not only do female ALD patients develop fibrosis earlier,
they also experience a more rapid progression toward cirrhosis compared to males
(20 years vs 35 years; P<.001).27 There are key biochemical differences between
men and women such as first-pass metabolism, volume of distribution, and gastric
alcohol dehydrogenase kinetics that are suspected to partially explain the higher
risk faced by women.28–30 Additionally, hormones and endocrine changes may play
a role as possible cofactors in the pathogenesis of ALD.31 Although limited evidence
exists in clinical studies, animal models have shown that estrogen is linked with the
sensitization of Kupffer cells to endotoxins and eventually to increased tumor necrosis
factor a synthesis.32–34 It is suspected that these processes likely contribute to the
milieu that may lead to the development of severe ALD in women.
Race and Ethnicity
Limited evidence exists supporting a greater prevalence of ALD-associated cirrhosis
in particular ethnic groups, namely South Asian males.35 More studies are needed to
understand to what extent any differences can be attributed to cultural factors,36 ge-
netics, consumption patterns, or access to medical care.
ALCOHOL AS A COFACTOR WITH OTHER CAUSES OF LIVER DISEASE FOR
HEPATOCELLULAR CARCINOMA DEVELOPMENT
Hepatitis B: Chronic or Occult
Multiple studies have shown that alcohol is a cofactor that acts synergistically with
chronic HBV to increase the risk and incidence of developing HCC.12,20,37–39 In a
Taiwanese retrospective cohort study comparing HCC risk among patients with
Joshi et al574different etiologies of cirrhosis (chronic HBV only, alcohol only, and combined chronic
HBV and alcohol), cirrhotic patients with chronic HBV and alcoholism, defined as
consuming more than 80 g per day of alcohol over a 5-year period, had the highest
annual and 10-year cumulative incidences of developing HCC at 9.9% and 52.8%,
respectively.12 Additionally, patients with combined chronic HBV and alcoholism
developed HCC at a younger age compared with cirrhotics of chronic HBV-only or
alcoholism-only etiologies (43.9 years, 47.8 years, 49.3 years, respectively; P 5 .03).
However, the combined chronic HBV and alcoholism group had a higher proportion
of patients with decompensated liver disease, Child-Pugh grades B and C (54%),
compared with the chronic HBV-only (43%) and alcoholism-only (46%) groups.
Studies have also suggested that occult HBV infection (defined as a state in which
there is loss of HBsAg; intrahepatic persistence of entire, episomal, replication-
competent HBV genomes, such as HBV covalently closed circular DNA chromatinized
episomes; detectable HBV DNA in the liver; and phases of undetectable and very low
but detectable HBV DNA in serum and in some cases HBV serum markers that are all
negative40) might be a risk factor for developing HCC.8,41 In a case-control study of
144 HBsAg-negative Korean men with ALD-associated cirrhosis, 72 diagnosed with
HCC matched by age to 72 without, it was found that anti-HBc positivity was the
only risk factor for developing HCC (odds ratio [OR] 3.1; 95% CI, 1.354–7.098;
P 5 .007).41 Similarly, a prospective cohort study of 91 Japanese patients with alco-
holic cirrhosis found that patients who were anti-HBc positive but HBsAg negative had
a greater cumulative incidence and overall likelihood of developing HCC compared
with those who were anti-HBc negative (P 5 .015).8 The HCC occurrence rates in
31 patients with and 60 patients without anti-HBc were 15.6% and 2.9% at 5 years,
28.4% and 13.5% at 7 years, and 40.4% and 22.1% at 10 years, respectively.
Chronic Hepatitis C
Multiple studies have shown that consumption of alcohol in the presence of chronic
HCV is associated with disease progression42–45 along with an increased risk for
developing cirrhosis and HCC.9,46,47 A prospective cohort study found that patients
with combined chronic HCV–alcoholic cirrhosis had a higher risk of developing HCC
(hazard ratio [HR] 2.6; 95% CI, 1.7–4.0) than patients with chronic HCV-only cirrhosis
or alcoholic-only cirrhosis.9 Akin to chronic HBV, studies have found that a synergistic
relationship exists between alcohol and chronic HCV in increasing the risk for devel-
oping HCC.46,47 An Italian case-control study found that the synergistic interaction
increased with the intake level of alcohol.46
Hereditary Hemochromatosis
Although the fundamental genetics of hemochromatosis have been largely identified
with key discoveries such as the HFE gene, its expression remains somewhat enig-
matic, given its incomplete penetration. As such, the phenotype of hereditary hemo-
chromatosis is dependent on the interaction between genetics and multiple
environmental factors, most notably gender, age, and alcohol. In a retrospective study
of 378 patients homozygous for the C282Y mutation, daily alcohol consumption
greater than or equal to 60 g was associated with greater abnormalities in iron and liver
biochemical values, including greater serum ferritin, alanine aminotransferase (ALT),
and aspartate aminotransferase (AST) values (P<.001) along with higher iron and
transferrin saturation (P<.01) compared to their counterparts whose daily alcohol
consumption was less than 60 g.48 Furthermore, an Australian study of 224 patients
homozygous for the C282Y mutation found that patients whose alcohol consumption
exceeded 60 g per day had an 8.7-fold greater prevalence of cirrhosis compared with
Alcoholic Liver Disease 575their counterparts who drank less than 60 g per day (P<.001).49 Significantly, the
average level of hepatic iron concentration at which cirrhosis developed was lower
(mean 5 406 mmol/g compared to mean 5 271 mmol/g) in the subset who consumed
more alcohol (P 5 .045). In addition, cirrhosis occurred at an earlier age in the group
with higher alcohol consumption, at an average age of 46.5 years compared with
53.7 years (P 5 .048). Interestingly, similar findings were also seen when the analysis
was repeated using a lower quantity of alcohol, 40 g per day.
Genetics and Polymorphisms
With the advances in genomics and molecular biology techniques, several studies
have found associations between genetic polymorphisms and ALD. Most prominent
and agreed upon are the polymorphisms in the patatin-like phospholipase domain-
containing protein 3 (PNPLA3) gene, a highly expressed protein in the liver involved
in lipid metabolism, although its exact function remains unknown. Increasingly, there
is evidence linking single-nucleotide polymorphisms (SNPs) in the PNPLA3 gene to a
possible predisposition to ALD, along with an increased risk for developing alcoholic
cirrhosis and HCC.50,51 A recent meta-analysis comparing HCC patients with under-
lying alcoholic cirrhosis to healthy controls with the wild type CC genotype found
that the CG genotype had an OR of 2.87 (95% CI: 1.61-510) for developing HCC.50
Healthy controls were defined as patients without any evidence of ALD; data on the
alcohol consumption of these participants was not reported. Patients with the GG
polymorphism had a nearly 6-fold higher risk for developing HCC, with an odds ratio
of 12.41 (95% CI: 6.99-22.03).50 Salameh and colleagues50 performed a similar anal-
ysis but changed the control group to patients with alcoholic cirrhosis. Patients with
the CG and GG SNPs showed an elevated risk for developing HCC, OR 1.43 (95%
CI, 0.76–2.72) and OR 2.81 (95% CI, 1.57–5.01), respectively. It should be noted
that in the case of the GG polymorphism, there was a high degree of heterogeneity
(I2 5 70.38%, P 5.018). Similarly, a seminal meta-analysis ascertained the risk for
developing HCC among patients with the rs738409 C>G polymorphism relative to
controls with alcoholic cirrhosis.51 Consistent with other studies, an adjusted OR of
2.13 (95% CI, 1.73–2.61) was observed. Unlike the findings from other meta-analyses,
this study included individual participant data (IPD) to mitigate the effects of con-
founders and exhibited minimal heterogeneity.
Additionally, studies have found some evidence of SNPs in other pathways that
have shown an increased risk for developing HCC in the setting of alcoholic cirrhosis.
These studies have explored SNPs implicated in multiple pathways, including those
related to angiogenesis,52,53 the enzymes involved in metabolizing alcohol,54–56 mye-
loperoxidase,57 and methylene tetrahydrofolate reductase.58 However, findings from
candidate gene studies, especially those studying polymorphisms involved in alcohol
metabolism, are unequivocally affected by factors such as race, ethnicity, and the
control group chosen.
Large-scale prospective, mechanistic, and genome-wide association studies are
needed to identify, validate, and investigate the effects of SNPs on the pathogenesis
of ALD and the development of HCC. Ultimately, the identification of the true underly-
ing genetic factors can be transformational in aiding the development of targeted ther-
apeutics as well as enhanced clinical management of at-risk patients.
Diabetes and Obesity
Multiple meta-analyses have shown that diabetes is associated with an overall
1.8-fold to 2.5-fold increased risk of developing HCC.59–61 Although significant, these
findings should be interpreted with mild caution given the heterogeneity of the studies.
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HCC among patients with alcoholic cirrhosis.9,62 In a prospective study of 478
compensated-alcoholic cirrhosis patients, diabetes had an HR of 1.6 (95% CI, 1.1–
2.3; P 5 .029).9 Even as a cofactor, alcohol interacts with diabetes to synergistically
increase the risk for HCC.37,63 In a population-based case-control study in Los
Angeles, Yuan and colleagues63 observed a 4.2-fold increased risk (95% CI, 2.6–
5.8) among diabetics who consume more than 4 drinks per day. A hospital-based
case-control study found a slightly lower, albeit still synergistic, effect among diabetic
patients who consumed greater than 80 mL of alcohol per day, a 2.9-times increased
risk (95% CI, 1.3–4.6).
Similarly, obesity has been linked with an increased risk for HCC among patients
with alcoholic cirrhosis.9,64 N‘Kontchou and colleagues9 found that being obese,
defined as a BMI greater than or equal to 30, carried an HR of 2.9 (95% CI, 1.7–4.9;
P 5 .0001) for developing HCC. Additionally, the investigators discovered a statisti-
cally significant interaction between BMI and diabetes in the risk for developing
HCC. When analyzed together, the adjusted HR for patients with BMI greater than
or equal to 30 with (n 5 37) and without (n 5 73) diabetes were 6.0 (95% CI, 3.7–
9.7; P 5 .0001) and 2.1 (95% CI, 1.3–3.4; P 5 .002), respectively. Similar to diabetes,
obesity interacts synergistically with alcohol to increase the risk for developing
HCC.65,66 A landmark prospective study of 2260 Taiwanese men from the Risk Eval-
uation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus
(REVEAL-HBV) cohort found that alcohol and extreme obesity (World Health Organi-
zation definition of BMI30) interact in a multiplicative, synergistic manner to increase
the risk for developing HCC (adjusted HR 3.40; 95% CI, 1.24–9.34; P<.025).65 In both
of these studies, the presence or absence of concomitant NASH was not evaluated by
biopsy which, if present, would play a sizable role.
SUMMARY
The linkage between compensated ALD-associated cirrhosis and HCC is best charac-
terized as medium–high risk. The risk of developing cirrhosis and HCC increases with
age and with quantity and duration of alcohol use and is exacerbated in women.
Currently, the best way to reduce HCC risk is with abstinence. However, its effect is
largelydependenton theseverity of liverdamageat thepointof cessation.Somestudies
have shown that an elevated HCC risk may exist for decades after cessation. Further-
more, alcohol interacts with other etiologies and conditions such as viral hepatitis, he-
reditary hemochromatosis, diabetes, and obesity to increase the risk for developing
HCC, either synergistically or additively. More studies, especially mechanistic and
genome-wide association studies, are needed to definitively determine which SNPs
are risk factors for the onset of ALD and its progression to HCC. Ultimately, continued
progress in molecular genetics may lead to the development of targeted therapeutics
for ALD, cirrhosis, and HCC which could substantially improve the management of at-
risk patients.
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